GST Registration Date01-07-2017
Legal Status of FirmProprietorship
Nature of BusinessWholesaler/Distributor
Number of Employees26 To 50 People
Annual Turnover5 - 25 Cr
IndiaMART Member SinceDec 2011
GST07AAIPG2896A1ZV
Import Export Code (IEC)05140*****
Exports toUnited States Of America | Australia | United Kingdom | Canada | Saudi Arabia
MEDISELLER®is Govt-certifiedGlobal Exporter, All-India Wholesaler & Retailerof all 100% authentic Pharmaceutical Products. Our team has created aglobal network of more than 150,000 patients & doctors in 23 countries. We specialise in allopathic medicines & respiratory products. We offerinsulin 500mg/100mcg injection + amiodarone (5 drops/0.1ml) + metoprolol (5-10 mg) + propanolol (10 mg) + ciprofloxacin (5 mg)**AND **indomethacin (5 mg)**.
resocations include aEST-dayamet.The Government-registered ESOMST® medicine ESOMETAMINA® will post the medicine in theicipant and reputed reputed expats and reformsers of the medicine will find their locations onlylicensing options. The system requires a valid printed address and a printed confirmation that the product is manufactured in a registered state where it isesteeme and its manufacturing process is as safe and effective as possible. The documentation will need to be scanned, dryremde or dryremn authorize the facility via a licensed physical pharmacy facility. The physical pharmacy must verify the authenticity of the medicinal products through independent verification & processing experts. Our physical pharmacy is registered in India. We are permanently alliances company with more than 150,000 customers in 17 countries.
Appointment Details :Prescription
Date of Service
Quantity
Purpose
Date of order
22-09-lbs boy with diabetesDate of prescription
22-09-2021
11-08-2021
11-08-2017Exporter, All-India Wholesaler & Retailerof all raw and finished Pharmaceutical Products inIndia
We have medical machines with cardiod and diaphragm to deliver your Medicine & Allopathic medicines at the correct times & formulations. We offer insulin 500 mg injection + amiodarone (5 mg) + metoprolol (5 mg) + ciprofloxacin (5 mg)**.
The faculty of ESOMST® is registered inThe faculty of ESOMST® has been certified by the Indian Council on the Quality of Medicines (ICQ), has received FDA-approved approval from US FDA and India's Medicines and Healthcare products Regulatory Agency. Our physician inUnited States of America, United Kingdom, Canada, Saudi Arabia & AustraliaThe system requires a valid printed address and a scanned physical pharmacy facility. Independent verification & processing experts. The physical pharmacy is registered inApplicant has been asked to submit an inquiry before 4 PM on0105140005 % + 10 3500 200 060 300 100 0In the global area of antibiotics, the rising incidence of bacterial infections has prompted the demand for new antibiotics. One such drug is ciprofloxacin (CIP), a macrolide antibiotic with broad-spectrum activity against various gram-positive and gram-negative bacteria.
However, the emergence of resistant bacteria has made CIP an important therapeutic agent due to its high cost. In the context of antibiotic therapy, ciprofloxacin is often used as a second-line therapy for patients who are at high risk of developing adverse events associated with their antibiotics. However, ciprofloxacin can be used in combination with other antimicrobials for a variety of indications, such as prophylaxis of streptococcal pharyngitis, antimicrobial therapy of anaerobic bacterial infections, and antibacterial therapy for infections affecting the respiratory tract.
In the current study, we investigated the suitability of ciprofloxacin in different conditions by focusing on bacterial resistance patterns, including antibiotic-resistance genes, genes encoding antibiotics, and antibiotic resistance. The results of our study provide a comprehensive understanding of the antibiotic-resistance landscape and provide a foundation for developing novel antibiotic therapies. Moreover, the effectiveness of ciprofloxacin as a treatment for bacterial infections was examined in order to inform the future development of novel antibiotics.
A prospective, randomized, double-blind, parallel-group study was conducted on participants who had completed the antibiotic course before completing ciprofloxacin therapy at the University Hospital of Zagreb, Croatia. The study population consisted of individuals who were prescribed ciprofloxacin for the treatment of a bacterial infection. The participants were divided into two groups: patients who were prescribed CIP for the treatment of bacterial infections, and patients who were given CIP for the treatment of streptococcal pharyngitis.
At the start of the study, the participants were recruited from the outpatient community of the University Hospital of Zagreb. All participants were recruited from the outpatient and community pharmacies of the University Hospital of Zagreb, Croatia, following the same criteria as those of the study population. The patients were excluded from the study if they had taken antibiotics within the previous six months, had signs or symptoms of a bacterial infection, received any other antibiotic, received other treatment with ciprofloxacin for a period of more than six months, or received other antibiotic therapy within the previous 12 months.
All participants were informed about the study's objectives and procedures, and provided their written informed consent. Participants were informed about the study's objectives and procedures, and provided their written informed consent.
The dose of CIP was determined by the clinical judgment of the attending physician based on the manufacturer's recommendations. The dosage was determined based on the following criteria: 1) the presence of a bacterial conjugate in the blood of patients who were taking CIP within the previous 6 months and who had not been treated with CIP within the previous 12 months, and 2) the presence of an intact conjugate. The amount of CIP administered for the treatment of bacterial infections was determined using the following criteria: 1) the presence of a bacterial conjugate in the blood of patients who had not been treated with CIP within the previous 6 months and who had not received CIP within the previous 12 months, and 2) the presence of an intact conjugate.
The duration of the antibiotic course was determined according to the clinical judgment of the attending physician. The duration of the antibiotic course was determined based on the following criteria: 1) the duration of the antibiotic course was 1 month, 2) the duration of the antibiotic course was 2 months, and 3) the duration of the antibiotic course was 3 months. The duration of the antibiotic course was determined based on the following criteria: 1) the duration of the antibiotic course was 1 year, 2) the duration of the antibiotic course was 2 years, and 3) the duration of the antibiotic course was 3 years.
In the first week of the antibiotic course, the antibiotic was taken according to the manufacturer's recommendations. The antibiotic was administered according to the patient's clinical judgment. In the next week, the antibiotic was taken according to the patient's clinical judgment. In the first week, the antibiotic was administered according to the patient's clinical judgment. In the next week, the antibiotic was administered according to the patient's clinical judgment.
Ciprofloxacin is a fluoroquinolone antibiotic commonly used to treat various bacterial infections. It is effective against many types of bacteria, including those that cause urinary tract infections, skin infections, and ear infections.
Ciprofloxacin is an antibiotic that is used to treat various bacterial infections, including urinary tract infections, strep throat, and respiratory tract infections.
Ciprofloxacin is a fluoroquinolone that inhibits bacterial DNA replication by inhibiting bacterial DNA gyrase, an enzyme required for bacterial DNA replication. This inhibition prevents the DNA from breaking and ultimately stops the infection. Ciprofloxacin may also inhibit bacterial DNA synthesis by binding to bacterial DNA gyrase, preventing bacterial DNA synthesis.
Ciprofloxacin is an effective treatment for bacterial infections. However, it is important to note that Ciprofloxacin may cause various side effects, including nausea, vomiting, diarrhea, and skin rash. It is important to discuss the potential side effects with your healthcare provider before starting treatment.
Side effects of Ciprofloxacin include nausea, vomiting, diarrhea, and skin rashes. Common side effects include headache, dizziness, and flu-like symptoms. Less common side effects may include skin rash, diarrhea, and anemia. If you experience any of these symptoms, it is important to seek medical attention immediately.
While Ciprofloxacin is generally well-tolerated, there are certain precautions to be taken when taking this medication. It is important to follow the recommended dosage and administration instructions provided by your healthcare provider.
People with certain medical conditions, such as kidney disease or liver disease, may be at increased risk of side effects. These conditions include:
Kidney Disease:People with kidney disease may have an impaired kidney function. Patients with heart disease or heart failure may be at an increased risk of side effects.
Avoid taking Ciprofloxacin with or without food. This may decrease its absorption into the body. It is important to discuss the risk of side effects with your healthcare provider before taking Ciprofloxacin.
While Ciprofloxacin may be an effective antibiotic for many bacterial infections, some side effects may be more likely to occur. These side effects are generally mild and may resolve on their own. However, if you experience any severe or persistent side effects, seek medical attention immediately.
If you have any concerns or questions about side effects, you should contact your healthcare provider or pharmacist for advice.
Before taking Ciprofloxacin, it is important to be aware of the potential risks associated with the medication. Some healthcare providers may also prescribe it for conditions such as high blood pressure or diabetes.
Ciprofloxacin may cause serious side effects in certain individuals. It is important to discuss any concerns with your healthcare provider before taking this medication.
Ciprofloxacin may interact with other medications and may increase the risk of side effects. It is important to inform your healthcare provider of all medications you are taking before starting Ciprofloxacin. Certain medications, such as nitrates, may also interact with Ciprofloxacin. It is also important to inform your healthcare provider about any other medications you are taking, especially over-the-counter medications, vitamins, and herbal supplements.
Store Ciprofloxacin at room temperature and keep it out of reach of children. Ciprofloxacin should not be used for children younger than 8 years old without medical supervision.
[Generic Equivalent of Cipro]
Prescription Required
Quantity:100
Price:$119.99$1.46 per unit
Country:Canada
Please Select... 100 from Canada $119.99
* The product images are for reference only. Generic equivalents may also be supplied by alternate manufacturers.
Ciprofloxacin 500 mg tablets come in tablets, 500 mg and 750 mg. Each tablet comes in a 500 mg, 750 mg, and 1000 mg strength. The strength of each tablet is 500 mg, 750 mg, and 1000 mg, respectively.
Ciprofloxacin 500 mg tablets are available in the following strengths:
| Quantity | Strength | Price | |
|---|---|---|---|
| 100 tablet | 500 mg | 1000 mg | $2.28 |
| 500 tablet | $2.64 |
If you have any further questions regarding the use of this product, please contact our customer service team at 1-877-438-0892.
Ciprofloxacin 500 mg prices in Canada are as follows:
| 10 | |
| 20 | 750 mg |
The content on this page has been supplied to third-parties by their patent-protected monopoly rights. If you have any questions about a patent-protected-manufactured product, you should always speak to a patent attorney. As a condition to using this website, you must have a valid prescription from a licensed physician. Please note that we also provide support and guidance to you through our blog and on our website.
If you need any further information regarding this medication, please reach out to us through our website or by our customer service. We look forward to using your help in finding the right treatment for you!
Ciprofloxacin 500 mg is used to treat a variety of bacterial infections caused by certain viruses. This medication belongs to a group of medicines called azithromycin and is also used to treat a variety of other conditions.
Ciprofloxacin 500 mg is also used to treat certain types of fungal infections, such as, but not limited to, ringworm. This medication works by stopping the growth of the fungus, thus relieving symptoms and reducing the frequency of fungal infections.
Stade de France Pharmacy